NCT02545127

Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely

A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Exploring the Efficacy and Safety of Intra-nasal Administration of Merotocin in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: Female
• Age: 18 Years – 44 Years
• Healthy volunteers: Not accepted

Summary

Induction and support of lactation in women with preterm delivery and inadequate milk production.

Conditions

• Preterm Delivery
• Inadequate Milk Production

Interventions

Type	Name	Description
DRUG	Merotocin	Merotocin nasal spray 400 μg/dose, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
DRUG	Placebo	Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).

Timeline

• Start date: 2021-05-28
• Primary completion: 2022-11-11
• Completion: 2022-11-11
• First posted: 2015-09-09
• Last updated: 2024-02-07
• Results posted: 2024-02-07

Locations

10 sites across 1 country: United States

Regulatory

• FDA-regulated drug study